Advertisement
BDX vs COO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. The Cooper Companies (COO) Stock Comparison
Key Takeaways
- BDX is reshaping into a focused MedTech (medical technology) company, while COO spans eyecare and women's health.
- BDX has raised its full-year adjusted EPS (earnings per share) outlook and announced a large U.S. manufacturing investment plan.
- COO recently cut its guidance amid contact lens channel destocking and saw a sharp post-earnings selloff.
- BDX pays a dividend and is using share buybacks aggressively; COO pays no dividend but has expanded its repurchase authorization.
- COO faces activist investor pressure for leadership and portfolio changes, adding execution uncertainty.
- On trend consistency and catalysts, BDX currently presents the more stable relative positioning.
Introduction
Investors evaluating healthcare names often weigh established medical technology franchises against specialized, higher-margin operators. This stock comparison looks at BDX (Becton, Dickinson and Company), a global leader in medical devices and diagnostics, and COO (The Cooper Companies), a manufacturer of contact lenses and women's health products. Both trade in the healthcare sector but serve very different end markets and carry distinct risk profiles. Traders focused on relative performance, market positioning, and momentum, as well as long-term investors weighing growth durability against execution risk, may find this side-by-side review useful for understanding how the two companies are navigating the current environment.
BDX Overview and Recent Performance
BDX is one of the world's largest medical technology companies, producing needles and syringes, blood collection systems, infusion pumps, drug delivery devices, and interventional products. A defining recent development has been its transition into a "pure-play" MedTech business following the planned separation of its Biosciences and Diagnostic Solutions segment and its combination with Waters. This restructuring aims to create a consumables-heavy portfolio (more than 90% of revenue) with more predictable cash flows and stronger margins.
In recent quarters, BDX reported solid organic growth, with management noting that more than 90% of its portfolio grew at a mid-single-digit rate and highlighting double-digit gains in biologic drug delivery, advanced patient monitoring, and GLP-1 (glucagon-like peptide-1) therapy-related platforms. The company also raised its full-year adjusted EPS guidance and announced a multi-year, roughly $19 billion U.S. investment plan, including about $3 billion directed toward expanding domestic manufacturing in exchange for tariff exemptions. These catalysts, combined with heavy share repurchases, have supported sentiment, though China weakness, tariffs, and execution risk around the separation remain headwinds.
COO Overview and Recent Performance
COO operates through two segments: CooperVision, a leading contact lens business with brands such as MyDay, Biofinity, and the pediatric myopia-control lens MiSight, and CooperSurgical, which supplies fertility, IVF (in vitro fertilization), and women's health devices, including the hormone-free Paragard IUD (intrauterine device). Cooper controls roughly one quarter of the U.S. contact lens market.
Recent market activity has been more turbulent for COO. Its latest fiscal quarter showed revenue roughly flat year over year, missing consensus estimates as proactive reductions in U.S. distribution channel inventory weighed on reported CooperVision sales, even though underlying U.S. consumption continued to grow at a mid-single-digit rate. Management lowered its near-term outlook, and shares fell sharply after the update. The company also concluded a strategic review by deciding to retain CooperSurgical, while activist investor JANA Partners has publicly called for leadership changes and a broader portfolio review. These developments have pressured sentiment and contributed to notable year-to-date underperformance.
Trending AI Robots
For traders seeking a data-driven perspective on stocks like BDX and COO, Tickeron's Trending AI Robots page offers a curated selection of automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of symbols. Because not every bot suits every market condition, only the strongest and most relevant strategies earn a place in the Trending section. The page highlights measurable statistics such as trade counts, win rates, and profit factors, helping users gauge how each bot has performed across changing market regimes. Explore the Trending AI Robots to see which strategies are currently favored.
Head-to-Head Comparison
The core contrast between these two stocks is scale and diversification versus specialization. BDX is a large, diversified MedTech operator whose business model emphasizes broad hospital and pharmaceutical exposure, a dividend, and significant cash returns to shareholders. Its growth drivers now center on injectable drug delivery, including GLP-1 therapies, and operational efficiency after its portfolio reshaping. Key risks include tariff and foreign exchange pressure, China demand, and the execution risk of its separation.
COO, by contrast, is a smaller, more focused company with structurally higher gross margins in its contact lens and fertility businesses. Its growth narrative leans on premium daily lenses, myopia management via MiSight, and fertility services. However, its near-term momentum has been disrupted by channel inventory adjustments, reduced guidance, and activist scrutiny, which have weighed heavily on its share price and created elevated uncertainty around leadership and portfolio direction.
In terms of relative performance, BDX has shown more consistent recent momentum and clearer catalysts, whereas COO is in a more defensive, transitional phase as it works through destocking and governance questions. Their sector exposures also differ: BDX skews toward acute and chronic care delivery, while COO spans consumer-oriented vision care and elective reproductive health.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor BDX at this stage of the cycle. The company demonstrates more consistent trend alignment, a raised earnings outlook, tangible catalysts such as GLP-1-related drug delivery partnerships and a U.S. manufacturing expansion, and a shareholder-friendly capital return program. In contrast, COO is contending with inventory destocking, softer guidance, and activist-driven uncertainty, which can translate into less stable price behavior in the near term. That said, probabilistic language is appropriate here: market conditions can shift quickly, and COO's high-margin franchises could regain favor once its inventory and governance issues resolve. Traders should weigh each name's trend stability and catalysts against their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Hold and COO is a StrongBuy.
BDX's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for BDX moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 19 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 57 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BDX just turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 27 of 48 cases over the following month. The odds of a continued upward trend are 56%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 133 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 111 of 219 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.128) is normal, around the industry mean (4.887). P/E Ratio (57.452) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.456). BDX has a moderately high Dividend Yield (0.022) as compared to the industry average of (0.006). P/S Ratio (2.290) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
COO's RSI Oscillator recovers from oversold territory
The RSI Indicator for COO moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 26 of the 36 cases the stock moved higher. This puts the odds of a move higher at 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on COO as a result. In 55 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for COO just turned positive on September 25, 2026. Looking at past instances where COO's MACD turned positive, the stock continued to rise in 25 of 42 cases over the following month. The odds of a continued upward trend are 60%.
Following a +1.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in 153 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The Aroon Indicator for COO entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. COO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.350) is normal, around the industry mean (4.887). P/E Ratio (20.177) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (0.532) is also within normal values, averaging (4.456). Dividend Yield (0.001) settles around the average of (0.006) among similar stocks. P/S Ratio (2.526) is also within normal values, averaging (56.074).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BDX | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 85 | 80 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 7 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (58) in the Medical Specialties industry is in the same range as BDX (71). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as COO (100). This means that BDX’s stock grew similarly to COO’s over the last 12 months.
COO's SMR Rating (80) in the Medical Specialties industry is in the same range as BDX (85). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
COO's Price Growth Rating (50) in the Medical Specialties industry is in the same range as BDX (50). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
BDX's P/E Growth Rating (7) in the Medical Specialties industry is significantly better than the same rating for COO (86). This means that BDX’s stock grew significantly faster than COO’s over the last 12 months.
| BDX | COO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 55% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 52% | 2 days ago 52% |
| Advances ODDS (%) | 6 days ago 45% | 2 days ago 56% |
| Declines ODDS (%) | 2 days ago 42% | 13 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 56% | N/A |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green while COO’s FA Score has 0 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- COO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while COO’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- COO’s TA Score: 4 bullish, 3 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +3.43% price change this week, while COO (@Pharmaceuticals: Other) price change was +8.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.77%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +7.55%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
COO is expected to report earnings on Dec 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +1.60% | ||
| COO - BDX | 55% Loosely correlated | +1.65% | ||
| TMO - BDX | 50% Loosely correlated | +1.18% | ||
| BAX - BDX | 50% Loosely correlated | -1.92% | ||
| CNMD - BDX | 48% Loosely correlated | +3.32% | ||
| MMSI - BDX | 48% Loosely correlated | +1.36% | ||
More | ||||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with A. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then A could also see price increases.